Lupus (SLE) trials in China

In China 163 Also abroad 354

163 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Beijing, Changchun, Chengdu, Guangzhou, Linyi, Nanchang, Nanjing, Ningbo, Pingxiang, Shanghai, Shantou, Suzhou, Ürümqi, Wenzhou, Xinxiang
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 3Taking people
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Where
Beijing, Binzhou, Changchun, Chongqing, Guangzhou, Liuzhou, Ningbo, Shanghai, Shantou, Shenyang, Shenzhen, Wuhan
Age
18 years to 100 years
People
348 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00
Phase 1Taking people
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Beijing, Pingxiang
Age
18 years to 75 years
People
46 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Ganzhou, Guangzhou
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Baotou, Changchun, Chengdu, Fuzhou, Guangzhou, Jinan, Luoyang, Nanjing, Shijiazhuang, Suzhou
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
No phaseNot yet taking people in China
MYTP01 for Immune-Mediated Diseases
Where
Hangzhou
Age
18 years to 65 years
People
160
Run by
Zhejiang Provincial People's Hospital
See details and how to joinNCT07901764
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua, Jining, Linfen, Luoyang, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shanwei, Suzhou, Taiyuan, Wenzhou, Xinxiang
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Guilin, Haikou, Hangzhou, Jinan, Jiujiang, Nanchang, Nanjing, Nanning, Pingxiang, Shanghai, Shantou, Shijiazhuang, Suzhou, Tianjin, Urumuqi, Wenzhou, Wuhan, Xiamen, Xi'an, Yangzhou, Zhengzhou, Zhuzhou
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
Phase 1Taking people
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Where
Beijing, Luoyang, Shanghai, Wuhan
Age
18 years to 75 years
People
21 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00
Phase 1Taking people
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Where
Beijing, Chengdu, Nanjing
Age
18 years to 65 years
People
48 worldwide
Run by
AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00
Phase 2Taking people
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Where
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai, Suzhou, Wenzhou
Age
18 years to 74 years
People
405 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Beijing, Chongqing, Guangzhou, Jinan, Lanzhou, Shanghai, Shenzhen
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 1Taking people
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
Where
Beijing, Bengbu, Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Luoyang, Nanjing, Shanghai, Suzhou, Taiyuan, Wuhan, Xiamen, Xi'an, Zhengzhou
Age
18 years and over
People
149
Run by
Antengene Biologics Limited
See details and how to joinNCT07732309
No phaseTaking people
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Where
Shanghai
Age
18 years to 65 years
People
6
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06379646
Phase 3Taking people
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
Where
Beijing, Bengbu, Changchun, Changde, Changlexi, Changsha, Chengdu, Dalian, Fuzhou, Guangdong Province, Guangzhou, Hangzhou, Harbin, Hefei, Hengyang, Hohhot, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Xiamen, Xi'an, Yangzhou, Yantai, Zhengzhou
Age
18 years to 70 years
People
417
Run by
AstraZeneca
See details and how to joinNCT07751848
Phase 1Taking people
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
12
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06978647
Phase 1Taking people
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Where
Hefei
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07104721
Phase 1Taking people
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Where
Tianjin
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07123519
Phase 1Taking people
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
Where
Beijing, Bengbu, Changsha, Chengdu, Guangzhou, Mianyang, Nanjing, Pingxiang, Shanghai, Taiyuan, Xian
Age
18 years to 60 years
People
117
Run by
Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT07323173
Phase 1/2Taking people
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Where
Baoji, Beijing, Bengbu, Changsha, Hefei, Mianyang, Nanchang, Suzhou, Taiyuan, Zaozhuang
Age
18 years to 65 years
People
30
Run by
Climb Bio, Inc.
See details and how to joinNCT07564596
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Beijing, Shanghai, Wuhan, Zhengzhou
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 1Taking people
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 65 years
People
12
Run by
Therorna
See details and how to joinNCT07413341
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Shantou, Suzhou, Tianjin, Wenzhou, Wuhan, Yangzhou, Zhengzhou
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1Taking people
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Where
Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
Age
18 years to 55 years
People
68 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07276958 · EU 2026-527207-25-00
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Beijing, Binzhou, Changchun, Changsha, Dongguan, Guangzhou, Haikou, Jiujiang, Ningbo, Pingxiang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Zhongshan, Zhuzhou
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00